Data layers Raw facts Calculated Model prediction AI interpretation

IPO Timeline Raw facts

Broker Deadline
Morning deadline
HKEX Deadline
Noon deadline
Broker Results (T-2)
Some brokers release in afternoon
Grey Market (T-1)
Afternoon
HKEX Allotment (T-1)
Evening
Registrar Allotment (T-1)
Evening
Listing Day (T)
First day of trading

Company Overview

Stock NameDualitybio-B
Stock Code09606
Company Full NameDuality Biotherapeutics, Inc.
Industry醫療保健
Principal Activities公司是全球抗體偶聯藥物(「ADC」)領域的主要參與者,致力于為癌癥和自身免疫性疾病等患者研發ADC創新藥物。
Listing Date2025-04-15
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國江蘇省蘇州市蘇州工業園區金谷路99號生物醫藥產業園三期B區項目3號樓301單元
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitehttps://www.dualitybiologics.com/
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism 18A生物科技
Offer PriceHK$ 94.60 / shares
Offer Price RangeFinal offer price only, no range
Lot Size100 shares
Entry ThresholdHK$ 9,460
Par ValueTo be extracted
Offer PeriodTo be extracted
Global Offering Shares17,332,300 shares
HK Public Offer Shares (Initial)To be extracted
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)To be extracted
Offer RatioTo be extracted
Total Shares Post-IPOTo be extracted
Greenshoe (Over-allotment Option)No
Stabilizing Manager (Greenshoe)—
Cornerstone Share30.8%
Clawback TiersTo be extracted
Reallocation OptionNo
Total Global Offering SizeHK$ 1,639,635,580

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 100 HK$ 9,460
2 lots 200 HK$ 18,920
3 lots 300 HK$ 28,380
4 lots 400 HK$ 37,840
5 lots 500 HK$ 47,300
6 lots 600 HK$ 56,760
7 lots 700 HK$ 66,220
8 lots 800 HK$ 75,680
9 lots 900 HK$ 85,140
10 lots 1,000 HK$ 94,600
15 lots 1,500 HK$ 141,900
20 lots 2,000 HK$ 189,200
25 lots 2,500 HK$ 236,500
30 lots 3,000 HK$ 283,800
35 lots 3,500 HK$ 331,100
40 lots 4,000 HK$ 378,400
45 lots 4,500 HK$ 425,700
50 lots 5,000 HK$ 473,000
60 lots 6,000 HK$ 567,600
70 lots 7,000 HK$ 662,200
80 lots 8,000 HK$ 756,800
90 lots 9,000 HK$ 851,400
100 lots 10,000 HK$ 946,000
200 lots 20,000 HK$ 1,892,000
300 lots 30,000 HK$ 2,838,000
400 lots 40,000 HK$ 3,784,000
500 lots 50,000 HK$ 4,730,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
600 lots 60,000 HK$ 5,676,000
700 lots 70,000 HK$ 6,622,000
800 lots 80,000 HK$ 7,568,000
900 lots 90,000 HK$ 8,514,000
1,000 lots 100,000 HK$ 9,460,000
1,500 lots 150,000 HK$ 14,190,000
2,000 lots 200,000 HK$ 18,920,000
2,500 lots 250,000 HK$ 23,650,000
3,000 lots 300,000 HK$ 28,380,000
3,500 lots 350,000 HK$ 33,110,000
4,000 lots 400,000 HK$ 37,840,000
4,500 lots 450,000 HK$ 42,570,000
5,000 lots 500,000 HK$ 47,300,000
6,000 lots 600,000 HK$ 56,760,000
7,000 lots 700,000 HK$ 66,220,000
7,536 lots 753,600 HK$ 71,290,560

Stock Connect Inclusion Analysis

HK Market Cap HK$ 19.68B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss StatusTo be extracted
Period-End Cash BalanceRMB 1,208.91 million
Listing Expenses~HK$ 120,300,000
Listing Expenses / Funds Raised~8.1%
Total Pre-IPO Investmentapproximately USD 137.5 million
First Day CloseHK$ 205.0
First Day OpenHK$ 181.0
First Day Change116.70%
First Day Volume10825200.0
First Day Turnover2030240000.0
Use of Proceeds
1、約45.0%(或616.6百萬港元)將用于研究、開發及商業化公司的核心產品(即DB1303及DB-1311); 2、約30.0%(或411.1百萬港元)將用于研發公司的關鍵產品; 3、約15.0%(或205.5百萬港元)將用于為公司ADC技術平臺的持續開發提供資金,推進公司的其他管線資產以及探索及開發新藥物資產; 4、約10.0%(或137.0百萬港元)將用于運營資金及其他一般公司用途。

Underwriting Syndicate

Joint Sponsors (3)
Morgan Stanley Asia Limited CE AAD291 Jefferies Hong Kong Limited CE ATS546 中信证券(香港)有限公司 CE AAK249
Sponsor cum Overall Coordinator (3)
Morgan Stanley Asia Limited CE AAD291 Jefferies Hong Kong Limited CE ATS546 中信里昂证券有限公司 CE AAB893
Overall Coordinators (5)
Morgan Stanley Asia Limited CE AAD291 Jefferies Hong Kong Limited CE ATS546 中信里昂证券有限公司 CE AAB893 中国国际金融香港证券有限公司 CE AEN894 招银国际融资有限公司 CE AVM940
Joint Global Coordinators (5)
Morgan Stanley Asia Limited CE AAD291 Jefferies Hong Kong Limited CE ATS546 中信里昂证券有限公司 CE AAB893 中国国际金融香港证券有限公司 CE AEN894 招银国际融资有限公司 CE AVM940
Joint Bookrunners (9)
Morgan Stanley Asia Limited CE AAD291 Jefferies Hong Kong Limited CE ATS546 中信里昂证券有限公司 CE AAB893 中国国际金融香港证券有限公司 CE AEN894 招银国际融资有限公司 CE AVM940 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 中银国际亚洲有限公司 CE AET863 广发证券(香港)经纪有限公司 CE AOB364 农银国际融资有限公司 CE AWL249
Joint Lead Managers (9)
Morgan Stanley Asia Limited CE AAD291 Jefferies Hong Kong Limited CE ATS546 中信里昂证券有限公司 CE AAB893 中国国际金融香港证券有限公司 CE AEN894 招银国际融资有限公司 CE AVM940 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 中银国际亚洲有限公司 CE AET863 广发证券(香港)经纪有限公司 CE AOB364 农银国际证券有限公司 CE ACX411
Capital Market Intermediaries (10)
Morgan Stanley Asia Limited CE AAD291 Jefferies Hong Kong Limited CE ATS546 中信里昂证券有限公司 CE AAB893 中国国际金融香港证券有限公司 CE AEN894 招银国际融资有限公司 CE AVM940 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 中银国际亚洲有限公司 CE AET863 广发证券(香港)经纪有限公司 CE AOB364 农银国际融资有限公司 CE AWL249 农银国际证券有限公司 CE ACX411

Service Providers

RoleInstitution
Legal Advisor to Company 凯易律师事务所
上海澄明则正律师事务所
君合律师事务所
Jun He Law Offices P.C.
Harney Westwood & Riegels
Legal Advisor to Sponsors/Underwriters 科律香港律师事务所
北京市通商律师事务所
Auditor and Reporting Accountant 罗兵咸永道会计师事务所
Industry Advisor 弗若斯特沙利文(北京)咨询有限公司上海分公司
Compliance Advisor 第一上海融资有限公司 CE AES612
Receiving Banks 招商永隆银行有限公司

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 BioNTech SE 38,871,140 HKD — 2.37% — 6 months 2025-10-15
2 Emerging Markets Healthcare Partners LLC 19,430,840 HKD — 1.19% — 6 months 2025-10-15
3 Lake Bleu Innovation Healthcare Master Fund Limited 13,991,340 HKD — 0.85% — 6 months 2025-10-15
4 Lake Bleu Prime Healthcare Master Fund Limited 24,879,800 HKD — 1.52% — 6 months 2025-10-15
5 LAV Star Opportunities Limited 38,871,140 HKD — 2.37% — 6 months 2025-10-15
6 MY Asian Opportunities Master Fund, L.P. 38,871,140 HKD — 2.37% — 6 months 2025-10-15
7 TruMed 77,751,740 HKD — 4.74% — 6 months 2025-10-15
8 Worldwide Healthcare Partners LLC 11,654,720 HKD — 0.71% — 6 months 2025-10-15
9 富国基金管理有限公司 37,158,880 HKD — 2.27% — 6 months 2025-10-15
10 富国资产管理(香港)有限公司 40,592,860 HKD — 2.48% — 6 months 2025-10-15
11 汇添富基金管理股份有限公司 46,647,260 HKD — 2.84% — 6 months 2025-10-15
12 盘京港景投资基金 38,871,140 HKD — 2.37% — 6 months 2025-10-15
13 苏州苏创生物医药大健康创业投资基金合伙企业(有限合伙) 15,542,780 HKD — 0.95% — 6 months 2025-10-15
14 易方达基金管理有限公司 57,223,540 HKD — 3.49% — 6 months 2025-10-15
15 易方达资产管理香港有限公司 4,975,960 HKD — 0.30% — 6 months 2025-10-15

Directors & Management

PositionChinese nameEnglish Name
Chairman朱忠遠—
Company Secretary袁佳麗,曾穎雯—
No director data available.

Major Shareholders

Major Shareholders & HoldingsLAV USD(20.04%),King Star Med LP(7.92%),上海楹伽企業管理合伙企業(有限合伙)(7.68%),WuXi Biologics HealthCare Venture(5.01%)
AI AI Analysis AI interpretation deepseek-v4-pro · AI-generated
!
Underlying data failed quality checks; AI interpretation downgraded and shown for reference only.

Market Sentiment

The IPO's oversubscription ratio of 115.14 signals intense retail demand. The hit rate of 92.34% is exceptionally high for such oversubscription, reflecting a 50% retail clawback under Mechanism A (old) that broadened allocations. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Tier Analysis

No tier-level application data is available to assess the efficiency of specific subscription tiers. The high overall hit rate suggests limited tier-based discrimination in allocation, but without granular data, anomalies cannot be identified. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Demographics

Demographic data shows 0 total holders with 0% Mainland and 0% Hong Kong participation, indicating missing or unreported statistics. Without reliable demographic figures, no patterns can be drawn. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

About this page

This page shows Dualitybio-B (09606) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect